Compare Kraft Heinz Co (KHC) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kraft Heinz Co vs Travere Therapeutics Inc. Common Stock — how do they compare? Kraft Heinz Co trades at $22.79 (market cap $26.60B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Kraft Heinz Co is far larger — about 5.5× Travere Therapeutics Inc. Common Stock's market cap, and Kraft Heinz Co pays a 7.13% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kraft Heinz Co for 129 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| KHC | TVTX | |
|---|---|---|
Market Cap | $26.60B | $4.88B |
Volume | 11,136,448 | 1,668,577 |
Sector | Consumer Staples | Health |
52-Week High | $27.62 | $67.52 |
52-Week Low | $21.21 | $26.79 |
Typical Hold Time | 129 Days | 0 Days |
Enterprise Value | $42.92B | $5.01B |
Dividend Yield | 7.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $22.70, up 1.11% on the day, with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals, including a negative net income margin of -13.64% for 2025 but a low P/B of 0.74, suggesting potential undervaluation. Recent news highlights the company's $700 million reinvestment plan and new product launches like Philadelphia cream cheese flavors to revive brands amid volume challenges.
The outlook remains cautious due to persistent profitability issues and high debt, though the dividend yield near 6.5% and analyst consensus price target of $24.11 offer some upside. Key risks include execution of the turnaround strategy and competitive pressures in the consumer goods sector.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
